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Abstract
Background: The opioid peptide dynorphin is expressed by certain neurons in the superficial dorsal horn of the
spinal cord, but little is known about the types of cell that contain dynorphin. In this study, we have used an
antibody against the dynorphin precursor preprodynorphin (PPD), to reveal the cell bodies and axons of
dynorphin-expressing neurons in the rat spinal cord. The main aims were to estimate the proportion of neurons in
each of laminae I-III that express dynorphin and to determine whether they are excitatory or inhibitory neurons.
Results: PPD-immunoreactive cells were concentrated in lamina I and the outer part of lamina II (IIo), where they
constituted 17% and 8%, respectively, of all neurons. Around half of those in lamina I and 80% of those in lamina II
were GABA-immunoreactive. We have previously identified four non-overlapping neurochemical populations of
inhibitory interneurons in this region, defined by the presence of neuropeptide Y, galanin, parvalbumin and
neuronal nitric oxide synthase. PPD co-localised extensively with galanin in both cell bodies and axons, but rarely
or not at all with the other three markers. PPD was present in around 4% of GABAergic boutons (identified by the
presence of the vesicular GABA transporter) in laminae I-II.
Conclusions: These results show that most dynorphin-expressing cells in the superficial dorsal horn are inhibitory
interneurons, and that they largely correspond to the population that is defined by the presence of galanin. We
estimate that dynorphin is present in ~32% of inhibitory interneurons in lamina I and 11% of those in lamina II.
Since the proportion of GABAergic boutons that contain PPD in these laminae was considerably lower than this,
our findings suggest that these neurons may generate relatively small axonal arborisations.
Background
Laminae I-III of the rat dorsal horn contain a large
number of densely packed neurons. Although ~5% of
the neurons in lamina I and some of those in lamina III
have long ascending axons that project to the brain, the
great majority of these cells are interneurons, with
axons that arborise locally [1]. The interneurons can be
divided into two major classes: excitatory (glutamater-
gic) cells, and inhibitory cells, which use GABA and/or
glycine as their principal fast transmitter [2]. We have
reported that GABA-immunoreactivity is present in 25-
30% of the neurons in laminae I-II and 40% of those in
lamina III, and that a sub-set of these cells show high
levels of glycine [3]. Most (if not all) of these inhibitory
cells are interneurons. The remaining neurons are gluta-
matergic, and these include both projection neurons and
excitatory interneurons.
Several distinct anti-nociceptive roles have been attrib-
uted to inhibitory interneurons in the superficial lami-
nae [4], and in addition, there appears to be a specific
population of these cells involved in preventing itch [5].
Less is known about the functions of the excitatory
interneurons, although some are thought to transmit
information from various types of primary afferent
(including nociceptors and low-threshold mechanore-
ceptors) to projection neurons [6,7].
Numerous studies have attempted to assign the inhibi-
tory and excitatory interneurons in this region to
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physiological criteria [1,8-20]. However, although certain
characteristic morphological types have been identified
[6,10,14-16,21], there is still no generally accepted classi-
fication scheme that can account for all of the inter-
neurons in this region [1,9].
An alternative approach to classifying interneurons
has been based on their expression of various neuro-
chemical markers, including neuropeptides. Among the
many neuropeptides that have been identified in dorsal
horn neurons, some (e.g. neurotensin, somatostatin and
neurokinin B) are found exclusively in excitatory neu-
rons, some (e.g. galanin and neuropeptide Y; NPY) only
in inhibitory neurons, while some (e.g. enkephalin) are
expressed by both excitatory and inhibitory cells [22-24].
Studies with immunocytochemistry and in situ hybri-
disation have identified the opioid peptide dynorphin in
certain dorsal horn neurons [25-39]. Most of the dynor-
phin-expressing cells are thought to be interneurons,
however, it has been reported that some of those in
lamina I are projection cells [30,32,39]. Relatively little is
known about the types of neuron that contain dynor-
phin, although at least some of these are likely to be
excitatory interneurons, since some axons containing
the peptide were immunoreactive with antibodies
against the vesicular glutamate transporter VGLUT2
[35], which is expressed at high levels by excitatory neu-
rons (but not by most primary afferents) in laminae I-III
[22,40]. Dynorphin can act at μ, δ and  opioid recep-
tors [41-43], each of which is expressed in the superfi-
cial dorsal horn [44], and also has non-opioid actions
that may contribute to neuropathic pain [45].
Dynorphin is normally present at very low levels in
the cell bodies of neurons that express the peptide,
but these can be revealed with antibody against the
precursor protein preprodynorphin (PPD) [39,46],
which is also present in dynorphin-containing axon
terminals [35]. The initial aims of this study were to
determine the proportions of neurons in laminae I-III
that contain PPD (and thus express dynorphin) and
to test whether any of these cells were GABAergic.
Since we found that many of the PPD neurons were
GABA-immunoreactive, we also determined the pro-
portion of GABAergic boutons (labelled with antibo-
dies against the vesicular GABA transporter, VGAT)
that contain PPD, and looked for coexistence of PPD
with other markers of inhibitory interneuron popula-
tions [1,47].
Methods
Animals
All experiments were approved by the Ethical Review
Process Applications Panel of the University of Glasgow,
and were performed in accordance with the European
Community directive 86/609/EC and the UK Animals
(Scientific Procedures) Act 1986.
Spinal cords obtained from 17 adult male Wistar rats
(230-330 g; Harlan, Loughborough, UK) were used in
this study. The rats were deeply anaesthetised with pen-
tobarbitone (300 mg i.p.) and perfused through the
heart with fixative that consisted of either 4% freshly
depolymerised formaldehyde (14 rats) or 4% formalde-
hyde/0.2% glutaraldehyde (3 rats) in phosphate buffer.
Tissue fixed with formaldehyde/glutaraldehyde was used
to analyse co-localisation of PPD and GABA, since
retention of GABA is greatly improved by glutaralde-
hyde fixation [48,49]. All other parts of the study were
carried out on tissue from the rats fixed with
formaldehyde.
Mid-lumbar (L3-L5) spinal segments were dissected
out and stored in the corresponding fixative for between
5 and 24 hours. These were then rinsed and cut into 60
μm thick transverse sections with a Vibratome. The sec-
tions were treated with 50% ethanol for 30 mins to
e n h a n c ea n t i b o d yp e n e t r a t i o n ,a n dt h o s ef r o ma n i m a l s
that had been fixed with formaldehyde/glutaraldehyde
were incubated with 1% sodium borohydride for 30
mins.
In several parts of the study, a tyramide signal amplifi-
cation (TSA) method was used, in order to minimise
the amount of primary antibody required. All immuno-
cytochemical reactions were carried out at 4°C. For
those involving TSA, antibodies were diluted in PBS
that contained 0.15 M NaCl, together with the blocking
serum supplied by the manufacturer. For reactions that
did not involve TSA, antibodies were diluted in PBS
that contained 0.3 M NaCl, and blocking serum was not
used. Incubations in primary and secondary antibodies
were for 3 days and overnight, respectively. Species-spe-
cific secondary antibodies (anti-IgG) were raised in don-
key and conjugated to Alexa 488 (Invitrogen, Paisley,
UK) or to Rhodamine Red, Cy5 or DyLight 649 (Jackson
I m m u n o r e s e a r c h ,W e s tG r o v e ,P A ,U S A ) .T h e s ew e r e
used at 1:500 (Alexa 488 and DyLight 649 conjugates)
or 1:100 (Rhodamine Red and Cy5 conjugates). Control
experiments were carried out for the TSA reaction by
omitting primary antibody, and these showed no
immunostaining.
Proportion of neurons in laminae I-III that were PPD-
immunoreactive
Sections from the L4 segments of 3 rats fixed with for-
maldehyde were incubated in guinea pig antibody
against PPD [46] (1:5,000) and mouse monoclonal anti-
body NeuN (Millipore, Watford, UK, catalogue number
MAB377; 1:500). The PPD was revealed with a TSA
reaction (tetramethylrhodamine kit; PerkinElmer Life
Sciences, Boston, MA, USA) and NeuN with secondary
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incubated in Sytox Green (Invitrogen; 1:50,000) for 30
mins at 20°C to reveal cell nuclei [24].
Two sections from each of the 3 animals were selected
(before PPD immunostaining was viewed) and scanned
with a Zeiss LSM710 confocal microscope with Argon
multi-line, 405 nm diode, 561 nm solid-state and 633
nm HeNe lasers. The sections were scanned through a
40× oil-immersion objective lens (numerical aperture
[NA] 1.3) to produce z-series consisting of 24 optical
sections at 1 μm z-separation. Between 6 and 8 contigu-
ous fields were scanned in order to cover the entire
cross-sectional area of laminae I-III. The confocal scans
were analysed with a modification of the disector
method [50-52], as described previously [53,54]. The
channels representing NeuN and Sytox were initially
opened in Neurolucida for Confocal software (Micro-
BrightField, Colchester, VT, USA), and an outline of the
grey matter was drawn from maximum intensity projec-
tions. The 14th and 22nd optical sections in each z-ser-
i e sw e r ed e s i g n a t e da st h er e f e r e n c ea n dl o o k - u p
sections, respectively. Every section in each series was
then viewed, and neuronal nuclei (identified by the pre-
sence of both NeuN and Sytox staining) that were pre-
sent in the reference section, or appeared in subsequent
sections, were marked on the drawing. All of those with
nuclei that were still present in the look-up section were
then excluded, leaving only neurons for which the lower
surface of the nucleus lay between reference and look-
up sections. The depth within the z-series at which the
nucleus of each of these selected cells was maximal was
recorded, to allow subsequent comparison of the depths
of PPD
+ and PPD
- neurons [54]. The channel corre-
sponding to PPD-immunostaining was then viewed, and
the presence or absence of PPD immunoreactivity in
each of the selected cells was noted. The borders
between laminae I, II and III were identified by overlay-
ing images obtained with a dark-field condensor, in
which lamina II can be recognised as a dark band due
to its lack of myelin [54,55]. The ventral border of
lamina III was drawn from a rat spinal cord atlas [56].
Since the frequency of PPD-immunoreactive neurons
appeared to differ considerably between the inner and
outer parts of lamina II, we divided lamina II by drawing
a line midway between its dorsal and ventral borders. In
this way, we were able to determine the proportions of
neurons in each lamina (and in the dorsal and ventral
halves of lamina II) that were PPD-immunoreactive.
Since the number of lamina I neurons included in these
sections was relatively low (15-30 per section), we also
scanned lamina I in an additional section from each of
the 3 animals. These were analysed in the same way,
except that only neurons in lamina I were included.
Although the reference and look-up sections are set
relatively far apart with this method, we were able to
ensure that all neurons with nuclei that lay between
these two planes were included in the sample, by exam-
ining every optical section between them. The positions
of reference and look-up sections within the z-series
were chosen to ensure that perikaryal cytoplasm at both
poles of the selected cells was visible in all cases. This
was done so that even cells with weak PPD staining
would be recognised.
PPD expression by GABA-immunoreactive neurons
Sections from the L4 segments of the 3 rats that were
fixed with formaldehyde/glutaraldehyde were incubated
in anti-PPD (1:100) and rabbit antibody against GABA
[57] (1:5,000), and these were revealed with secondary
antibodies conjugated to Rhodamine Red and Alexa 488,
respectively. Six sections from each animal were
selected, before immunostaining was viewed, and these
were scanned with the confocal microscope through a
40× oil-immersion lens. For each section 6-8 adjacent z-
series, each with 1 μm z-separation, were scanned in
such a way as to cover the entire area of laminae I-IV
on one side of the spinal cord. Since penetration of the
GABA-immunostaining was extremely limited, only the
superficial parts of each section were scanned.
The confocal images were analysed with Neurolucida
for Confocal. The channel corresponding to PPD was
initially viewed, and all PPD-immunoreactive neurons
for which part of the nucleus appeared at the top sur-
face of the Vibratome section were plotted onto an out-
line of the dorsal horn. The GABA channel was then
revealed, and the presence or absence of GABA-immu-
noreactivity in each of the selected neurons was
recorded. In order to determine whether differences in
the sizes of GABA
+ and GABA
- neurons could have led
to a bias in selection, we estimated the distance in the
z-axis between the upper surface of the Vibratome sec-
tion and the bottom of the nucleus for each cell, by
counting the number of optical sections between these
levels.
Proportion of GABAergic boutons that were PPD-
immunoreactive
Antibody against VGAT was used to reveal GABAergic
axonal boutons [58-60]. VGAT (which is sometimes
referred to as the vesicular inhibitory amino acid trans-
porter) is also expressed by glycinergic axon terminals
[58]. However, most glycinergic axons in laminae I-III
are likely to use GABA as a co-transmitter, since vir-
tually all of the glycine-enriched neurons in this region
are GABA-immunoreactive [2]. For simplicity, we refer
to VGAT-positive structures as GABAergic. It is unli-
kely that a significant number of GABAergic/glycinergic
boutons in this region lack detectable VGAT, since we
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files in laminae I-III of the rat dorsal horn are associated
with a VGAT-positive bouton [61], and gephyrin is
thought to be present at the post-synaptic aspect of
most (if not all) GABAergic and glycinergic synapses
[62].
Sections from 3 rats that had been fixed with formal-
dehyde were incubated in guinea pig anti-PPD (1:100),
mouse monoclonal anti-VGAT (Synaptic Systems, Göt-
tingen, Germany; catalogue number 131 011; 1:1,000)
and rabbit antibody against protein kinase Cg (PKCg;
Santa Cruz Biotechnology, Santa Cruz, CA, USA; catalo-
gue number sc-211; 1:1,000). These were revealed with
secondary antibodies conjugated to Alexa 488, Cy5 and
Rhodamine Red, respectively. Two sections from each
rat were selected (before PPD immunostaining was
viewed) and scanned with the confocal microscope
through a 63× oil-immersion lens (NA 1.4) to produce a
set of 4 contiguous z-stacks (each consisting of 25 opti-
cal sections at 0.3 μm z-separation) that formed a 100
μm wide vertical strip through laminae I-III in the cen-
tral part of the dorsal horn on one side. The confocal
images were analysed with Neurolucida for Confocal
software, as described previously [47,54,61]. Briefly, the
image stacks were aligned and the outline of the dorsal
horn, together with laminar boundaries, was drawn
from scans obtained with a dark-field condensor [55]
and from the location of the dense plexus of PKCg-
immunoreactivity, which occupies the inner half of
lamina II [63]. The VGAT channel was initially viewed,
and 300 immunoreactive boutons (100 from each of
laminae I, II and III) were selected from a single optical
section near the middle of the z-series. The selection
was performed by applying a 5 μm×5μmg r i da n d
choosing the bouton nearest the lower right hand corner
of each grid square, starting at the most dorsal part of
the lamina and working from dorsal to ventral, and then
from left to right. Once the boutons had been selected,
the PPD channel was viewed, and the presence or
absence of PPD-immunostaining in each VGAT bouton
was recorded. Since this sampling method will be biased
towards boutons that are more extensive in the z-axis,
we measured the z-axis length of all selected boutons by
multiplying the number of z-sections on which they
appeared by the z-separation between optical sections
(0.3 μm).
Relationship between PPD and markers of inhibitory
interneurons
We have previously shown that NPY, galanin, neuronal
nitric oxide synthase (nNOS) and parvalbumin are pre-
sent in 4 distinct, non-overlapping populations of inhibi-
tory interneurons in the superficial dorsal horn of the
rat spinal cord [47,64]. In order to determine whether
dynorphin was expressed by any of these populations,
we reacted sections from the L3-L5 segments with gui-
nea pig anti-PPD (1:5,000) and either rabbit anti-NPY
(Bachem, St Helens, UK; catalogue number T-4070;
1:1,000), rabbit anti-galanin (Bachem, St Helens, UK;
catalogue number T-4334; 1:1,000); rabbit anti-parvalbu-
min [65] (1.24 μg/ml) or sheep anti-nNOS [66]
(1:2,000). In each case PPD was revealed with a TSA
method (as described above) and the other antigen with
a secondary antibody conjugated to Alexa 488.
Sections from 3 rats that had been reacted with each
of these antibody combinations were scanned with the
confocal microscope through a 40× oil-immersion
objective to produce a set of z-series (2 μm z separation)
that covered the entire area of lamina I and II on one
side. Two sections were scanned from each animal for
each combination, and these were analysed with Neuro-
lucida. In each case, the channel corresponding to PPD
was viewed first, and the positions of all immunoreactive
neurons in laminae I and II were recorded. The other
channel was then viewed, and the presence or absence
of the other marker (NPY, galanin, parvalbumin or
nNOS) was recorded. Since we found a high degree of
co-localisation of PPD with galanin (see below), we also
identified all of the neurons that were galanin-immunor-
eactive but lacked PPD, and in this case, we analysed
cells in laminae I and II separately.
To test for co-localisation of PPD and galanin in
GABAergic axonal boutons, we reacted sections from
the L4 or L5 segments of 3 rats with guinea pig anti-
PPD (1:100), rabbit anti-galanin (1:1,000) and goat anti-
VGAT [67] (1:5,000), and these were revealed with sec-
ondary antibodies conjugated to Rhodamine Red, Alexa
488 and DyLight 649, respectively. A single section from
each animal was scanned with the confocal microscope
through the 63× oil-immersion lens, exactly as described
above (for PPD, VGAT and PKCg), except that only
laminae I and II were included in the scans. The result-
ing z-series were analysed with Neurolucida. In each
case, the PPD and VGAT staining were initially viewed,
and 100 PPD
+/VGAT
+ boutons were selected from the
superficial dorsal horn in each section. The galanin
staining was then viewed, and the presence or absence
of galanin-immunoreactivity in each of the selected bou-
tons was recorded. The analysis was then repeated in
the same way, except that 100 galanin
+/VGAT
+ boutons
were selected from each section and then examined for
the presence of PPD.
Characterisation of antibodies
The PPD antibody was raised against a peptide corre-
sponding to amino acids 229-248 at the C terminus of
rat preprodynorphin, which was conjugated to keyhole
limpet haemocyanin. It has been shown to label PPD,
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blocked by pre-absorption with the immunising peptide
[46].
The monoclonal antibody NeuN, raised against puri-
fied cell nuclei from mouse brain, detects a protein spe-
cific to neurons [68], and we have reported that it
appears to label all neurons (and no glial cells) in the
rat spinal cord [55]. The GABA antibody was raised
against GABA conjugated with glutaraldehyde to por-
cine thyroglobulin, and shows negligible cross-reactivity
against other amino acids, including glutamate, aspar-
tate, glycine or taurine [57]. We have shown that immu-
nostaining with the NPY antibody in the dorsal horn
c a nb ea b o l i s h e db yp r e - i n c u b ation with synthetic NPY
[69]. The nNOS antibody labels a band of 155 kDa in
Western blots of rat hypothalamus, and immunostaining
is abolished by pre-incubation in nNOS [66]. The par-
valbumin antibody was raised against mouse parvalbu-
min and recognises a single band of 13 kDa in blots of
mouse brain homogenates [65]. The galanin antibody
detects rat galanin, but not substance P, vasoactive
intestinal polypeptide or NPY (manufacturer’s specifica-
tion), and it has been reported that staining with this
antibody is absent from the brains of galanin knock-out
mice [70]. The mouse monoclonal VGAT antibody
(raised against amino acids 75-87 of mouse VGAT)
labels a single band of 57 kDa in blots of mouse brain
and retina, and immunostaining is blocked by pre-
absorption with the immunising peptide [71]. No stain-
ing with this antibody is seen in Western blots from cul-
tured neurons obtained from VGAT
-/- mice [72]. The
goat VGAT antibody (raised against amino acids 21-112
o fm o u s eV G A T )a l s os t a i n sas i n g l eb a n do f5 7k D ai n
blots of brain extracts, and we have found that this
stains identical structures in rat dorsal horn to the
mouse VGAT antibody (E. Polgár and A.J. Todd,
unpublished observations). We have reported that the
rabbit PKCg antibody stains identical structures to a
well-characterised guinea-pig antibody [61], and staining
with the latter antibody is absent from the brains of
PKCg knock-out mice [73].
Statistical tests
The Mann-Whitney U-test was used for statistical analy-
sis, and p < 0.05 was taken as significant.
Results
PPD immunoreactivity in laminae I-III
The laminar distribution of PPD immunoreactivity was
consistent with that which has been reported previously
in the rat spinal cord with antibodies against dynorphin
[28,33,35] or PPD [35,37]. Axonal immunostaining,
which consisted of fibres and associated varicosities, was
present throughout the dorsal horn (Figure 1). These
axons formed a dense plexus in lamina I and the outer
part of lamina II (lamina IIo), and were also fairly
numerous throughout the deepest parts of the dorsal
horn (laminae IV-VI). However, there were relatively
few PPD-immunoreactive axons in the inner part of
lamina II (lamina IIi) or in lamina III. PPD-immunor-
eactive cell bodies were frequently seen in the superficial
region (laminae I-IIo), but only occasionally in deeper
laminae. Within these cells, the immunoreactivity was
present in the form of numerous fluorescent granules
that occupied the perikaryal cytoplasm, with limited
extension into proximal dendrites (Figure 2a). PPD-
immunoreactive profiles (both axons and cell bodies)
were seen throughout the depth of the Vibratome sec-
tions, indicating that there was good penetration of anti-
bodies into the tissue.
The results of the quantitative analysis of PPD expres-
sion in neurons in laminae I-III are shown in Table 1,
and an example of PPD and NeuN immunostaining in
Figure 2. PPD was present in 17.1% of lamina I neurons,
4.3% of those in lamina II and 0.7% of those in lamina
III. When lamina II was divided into outer and inner
halves, the proportions of neurons in these that were
PPD-immunoreactive were 7.6% and 0.4%, respectively.
The depths at which the nuclei of the PPD
+ cells in the
sample were maximal ranged from 5 to 14 μmb e l o w
Figure 1 PPD immunoreactivity in the rat dorsal horn.A
confocal image from a transverse section of the L4 segment
showing the laminar distribution of PPD. There is a dense band of
immunostaining that occupies lamina I and lamina IIo, with variable
extension into lamina IIi. This region contains several
immunoreactive cell bodies, which are seen more clearly in the
inset (corresponding to the box in the main image). Four
immunoreactive cells are indicated with arrows. Lamina III contains
a few scattered immunoreactive axons, while these are somewhat
more numerous in laminae IV-V. The main image is a projection of
27 optical sections, while the inset is a projection of 2 sections. In
each case the z-spacing is 2 μm. Scale bar = 100 μm
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sponding values for PPD
- cells were 2 to 21 μm (median
11 μm, n = 1196), and these values did not differ signifi-
cantly (p = 0.12; Mann-Whitney U-test). This suggests
that there was no reduction in the proportion of neu-
rons that were PPD-immunoreactive at deeper levels
within the z series, which would have occurred if there
had been incomplete penetration of immunostaining.
PPD and GABA
The distribution of GABA immunostaining was very
s i m i l a rt ot h a tr e p o r t e dp r e v i o u s l yi nt h er a td o r s a l
horn [2,3]. Staining was particularly dense in laminae
I-III, and this region contained numerous immunor-
eactive cell bodies (Figure 3). Non-immunoreactive
cells stood out as dark areas, surrounded by strongly
immunoreactive structures in the neuropil, which pre-
sumably corresponded to dendrites and axonal boutons
of GABAergic neurons. However, as reported pre-
viously for Vibratome sections [61,74], the penetration
of GABA immunostaining was extremely limited (less
than 5 μm), and we therefore only examined cells for
which the nucleus appeared on the top surface of the
section. As in the formaldehyde-fixed tissue, numerous
PPD-immunoreactive cells were present in laminae I-
II, with scattered cells in deeper laminae. Examples of
PPD cells that were GABA-immunoreactive, or non-
immunoreactive are illustrated in Figure 3, while the
locations of all the PPD cells tested for GABA-immu-
noreactivity are shown in Figure 4, and quantitative
data for those in laminae I-III are provided in Table 2.
The majority of the PPD cells that were selected in
laminae I-II (143/208, 69%, data pooled from 3 rats)
were GABA-immunoreactive, while all of the cells in
lamina III and below were negative for GABA. Within
the superficial dorsal horn, GABA-immunoreactivity
Figure 2 Confocal images showing PPD-immunoreactive cells in lamina I and IIo. a: Part of the L4 segment scanned to reveal PPD (red). b:
The same field scanned for NeuN (blue) and Sytox (green). c: Merged image, with the solid line representing the dorsal border of the grey
matter, and the two dashed lines the dorsal and ventral borders of lamina II. Three PPD-immunoreactive cells (asterisks) are present, one in
lamina I and 2 in lamina IIo. Note that these are stained with NeuN, indicating that they are neurons. Many other neurons that are not PPD-
immunoreactive are also visible. The nuclei of non-neuronal cells lack NeuN, and therefore appear green. The small red profiles include PPD-
immunoreactive axons and dendrites. The images were obtained from a single optical section. Note that some neuronal nuclei appear very
small, because the optical section does not go through their maximum diameter. Scale bar = 20 μm.
Table 1 Percentages of neurons in laminae I-III that were PPD-immunoreactive
Lamina Number of neurons counted Number of PPD
+ cells % of neurons that were PPD
+
I 68.7
(60-76)
11.7
(11-13)
17.1
(15.7-18.3)
II 205.7
(183-221)
9
(7-10)
4.3
(3.8-4.7)
IIo 113.3
(105-129)
8.7
(6-10)
7.6
(5.7-9.5)
IIi 92.3
(77-108)
0.3
(0-1)
0.4
(0-1.3)
III 146
(127-170)
1
(0-2)
0.7
(0-1.4)
In each case the mean values for the 3 animals are shown, with the range in brackets.
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t h o s ei nl a m i n aI I .
Since both GABA
+ and GABA
- PPD cells were found
in laminae I-II, we compared the distances between the
top of the Vibratome section and the bottom of the
nucleus for all of the cells in both populations within
this region. Because each nucleus can be cut through
any part of its z-axis length, the mean of this distance
should correspond to half of the mean z-axis length of
the nucleus in a large population of cells. The mean
distance was 7.26 μm( r a n g e1 - 1 5μm, median 7 μm, n
=1 4 3 )f o rt h eG A B A
+ neurons, and 8.17 μm( r a n g e1 -
14 μm, median 9 μm, n = 65) for the GABA
- cells.
These values did not differ significantly (p = 0.074,
Mann-Whitney U-test), which suggests that bias towards
selecting larger cells was unlikely to have influenced our
estimate of the proportion of PPD neurons that were
GABA-immunoreactive.
PPD and VGAT
In the sections reacted for VGAT and PPD, the distribu-
tion of VGAT-immunostaining was the same as that
reported previously [54], with numerous VGAT-immu-
noreactive boutons being present throughout the entire
dorsal horn. PPD-immunoreactivity was found in some
of the VGAT boutons (Figure 5), particularly in laminae
Figure 3 Expression of PPD by GABA-immunoreactive and
non-immunoreactive neurons. a-c: Confocal images of a
transverse section of the L4 segment from a rat that had been fixed
with glutaraldehyde/formaldehyde and reacted with antibodies
against PPD (magenta) and GABA (green). This field shows a single
PPD-immunoreactive neuron in lamina IIo (arrow), which is GABA-
immunoreactive and is surrounded by other GABA-immunoreactive
neurons, as well as by neurons that lack GABA, three of which are
indicated with asterisks. Note that the PPD occupies the perikaryal
cytoplasm but is excluded from the nucleus, whereas GABA staining
is seen throughout the nucleus and cytoplasm. Also, note that there
is a high density of punctate GABA immunoreactivity throughout
the neuropil, which consists of the dendrites and axons of
GABAergic neurons. The GABA-negative neuronal cell bodies stand
out as dark “holes” within this neuropil staining. d-f: a PPD-
immunoreactive neuron (arrowhead) near the lamina II/III border
that is not GABA-immunoreactive. Both sets of images are from a
single optical section. Scale bar = 10 μm.
Figure 4 The laminar location of GABA-immunoreactive and
non-immunoreactive PPD neurons. A plot showing the
distribution of all of the PPD cells that were analysed for GABA-
immunoreactivity in the three rats that were fixed with
glutaraldehyde/formaldehyde. Each symbol represents a single PPD
neuron. The GABA-immunoreactive cells are shown as filled circles
and the GABA-negative cells as open circles. Note that while the
majority of cells (143/208) in the superficial dorsal horn (laminae I-II)
are GABA-immunoreactive, all of the PPD cells ventral to this region
are GABA-negative.
Table 2 Percentages of PPD neurons sampled in laminae
I-III that were GABA-immunoreactive
Lamina Number of PPD cells counted % that were GABA
+
I 22.7
(17-28)
46.6
(39.1-53.6)
II 46.7
(42-51)
79.1
(73.8-85.1)
III 5.7
(5-7)
0
In each case the mean values for the 3 animals are shown, with the range in
brackets.
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Page 7 of 14I and IIo. Quantitative analysis revealed that 4.2% of the
VGAT boutons in both lamina I and lamina II were
positive for PPD, but very few (0.2%) of those in lamina
III were PPD-immunoreactive (Table 3). When lamina
II was subdivided into outer and inner halves, the
proportions of VGAT boutons that were PPD
+ were
6.8% in IIo and 2.1% in IIi.
The mean of the z-axis lengths for the PPD
+ boutons
in laminae I, IIo and IIi were 1.67 μm (range 0.6-2.4
μm, n = 25), 1.68 μm (range 1.2-2.7 μm, n = 18) and
1.63 μm (range 1.5-2.1 μm, n = 7), respectively, while
those for the PPD
- boutons in these laminae were 1.59
μm( r a n g e0 . 3 - 3 . 6μm, n = 575), 1.48 μm( r a n g e0 . 3 - 3 . 6
μm, n = 249) and 1.48 μm( r a n g e0 . 3 - 3 . 3μm, n = 326).
Mann-Whitney U-tests showed that there was no signif-
icant difference between the sizes of the PPD
+ and PPD
-
VGAT boutons in any of these regions (p = 0.28 for
lamina I, 0.09 for lamina IIo, 0.26 for lamina IIi). It is
therefore unlikely that our sample was biased towards
either PPD
+ or PPD
- boutons among the VGAT
population.
Colocalisation of PPD with nNOS, parvalbumin, NPY and
galanin
The distribution of nNOS, parvalbumin, galanin and
NPY was identical to that reported previously in the rat
dorsal horn with these antibodies [47]. Results of the
quantitative analysis are provided in Tables 4 and 5,
and confocal images showing the relationship between
PPD and each of these compounds are illustrated in
Figure 6.
In sections reacted with nNOS and PPD antibodies
there was some overlap in the laminar distribution of
cells with the two types of immunoreactivity. However,
none of the 237 PPD
+ cells selected was nNOS-immu-
noreactive (Figure 6a-c). Parvalbumin-immunoreactive
cells were largely restricted to the deepest part of lamina
II and were relatively numerous in lamina III, thus dif-
fering in their distribution from the PPD cells. None of
the 324 PPD cells examined in these sections was par-
valbumin-immunoreactive (Figure 6d-f). NPY-immunor-
eactive cells were found throughout laminae I-III,
however, few of the PPD cells examined (21/308, 6.8%)
were double-labelled (Figure 6g-i). Three of the double-
labelled cells were located in lamina I and 18 in lamina
Figure 5 PPD and VGAT immunoreactivity in lamina I. a, b:
Confocal images scanned to reveal PPD (green) and VGAT
(magenta). c: a merged image. Many VGAT boutons are visible
throughout the field, and 3 of these (arrows) are also PPD-
immunoreactive. The asterisk in a and c indicates part of a PPD
+
cell body. The images are projections from 3 optical sections at 0.3
μm z-separation. Scale bar = 5 μm.
Table 3 Percentages of VGAT boutons in laminae I-III
that were PPD-immunoreactive
Lamina VGAT boutons analysed % VGAT boutons PPD
+
I 600 (200) 4.2 (3 - 5.5)
II 600 (200) 4.2 (3 - 5)
IIo 267 (87-90) 6.8 (4.4 - 9.2)
IIi 333 (110-113) 2.1 (1.8 - 2.7)
III 600 (200) 0.2 (0 - 0.5)
The second column shows the total number of VGAT boutons from each
lamina (or sublamina) that were analysed, with the range per animal (n = 3
rats) shown in brackets. The mean percentages of the VGAT-positive boutons
that were PPD-immunoreactive are shown in the third column, with ranges
per animal in brackets.
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Page 8 of 14II, and all of them were weakly stained with the NPY
antibody.
In contrast, there was extensive co-localisation of PPD
and galanin in neurons in the superficial dorsal horn
(Figure 6j-l; Table 5). In lamina I, 47% of the PPD neu-
rons were galanin-immunoreactive, and double-labelled
cells constituted 96% of the galanin-containing popula-
tion. In lamina II, 70% of the PPD cells were galanin-
positive, and double-labelled cells made up 92% of those
that contained galanin. Although scattered PPD
+ and
galanin
+ cells were observed in deeper parts of the dorsal
horn (laminae III-IV) in these sections, none of these
were double-labelled. There was also extensive co-locali-
sation of PPD and galanin immunoreactivities in VGAT
boutons in the superficial dorsal horn (Figure 7). Among
the PPD
+/VGAT
+ boutons, 93.3% (range 92-94%, n = 3
rats) were galanin-immunoreactive, while 91.3% (range
91-92%) of the galanin
+/VGAT
+ boutons contained PPD.
Discussion
The main findings of this study are: (1) that cells expres-
sing PPD are relatively common in the superficial dorsal
horn, constituting 17% of neurons in lamina I and 4% of
those in lamina II, (2) that the majority of these (69%) are
GABAergic, and (3) that among the neurochemical popu-
lations of inhibitory interneurons that have been identi-
fied in the rat dorsal horn [47,64], the PPD cells overlap
extensively with those that contain galanin, but not with
those that express nNOS, NPY or parvalbumin.
Dynorphin-expressing neurons
The concentration of dynorphin in the cell bodies of
neurons that synthesise the peptide is normally too low
to be detected by immunocytochemistry, either because
dynorphin is rapidly transported away from soma to
axon terminals, or becausei ti so n l yp r o d u c e df r o m
PPD within the axon. Most of the early studies that
investigated the distribution of dynorphin-containing
cells in the spinal cord therefore used colchicine to
block axoplasmic transport and increase perikaryal label-
ling [26-32]. However, it is now known that colchicine
can alter the mRNA levels for neuropeptides [75-77],
and may even cause de novo synthesis of these peptides
by neurons that do not normally express them [75,77].
In order to avoid the need for colchicine, we used an
antibody against the precursor protein, PPD, which can
be detected in neuronal cell bodies in both brain and
spinal cord [35,46]. It has also been shown that PPD
and dynorphin are co-localised in axon terminals in the
dorsal horn [35], indicating that PPD antibody can be
used to reveal the axons of dynorphin-containing cells.
The distribution of PPD-immunoreactive neuronal cell
bodies that we saw is the same as that reported by Mar-
vizon et al. [35], who used a different PPD antibody and
also closely resembles that of PPD mRNA
+ cells
detected with in situ hybridisation in rat [31] and mouse
[36]. In addition, the laminar location of PPD-immunor-
eactive axons was very similar to that of dynorphin-con-
taining axons reported in various species in previous
immunocytochemical studies [25,28,33-35]. Many of
t h e s ea x o n sa r el i k e l yt oo r i g i n a t ef r o ml o c a lP P D -
expressing cells, however, some are of primary afferent
origin [35]. In addition, the presence of PPD in the dor-
solateral funiculus raises the possibility that there are
dynorphin-containing axons originating in the brainstem
that project to the spinal cord.
Table 4 Lack of co-localisation of PPD with nNOS, parvalbumin and NPY in laminae I-II
Number of PPD cells examined Number positive for other marker % positive for other marker
nNOS 79
(68-92)
00
Parvalbumin 108
(87-129)
00
NPY 102.7
(92-113)
7
(4-10)
6.8
(3.9-8.8)
In each case the mean values for the 3 animals are shown, with the range in brackets.
Table 5 Co-localisation of PPD with galanin
Lamina Number of PPD
cells
Number of galanin
cells
Number of double-labelled
cells
% of PPD cells with
galanin
% of galanin cells with
PPD
I4 3
(38-46)
20.7
(19-24)
20
(18-24)
46.6
(39.1-53.3)
96.5
(94.7-100)
II 89.3
(70-108)
67.3
(55-74)
61.7
(54-68)
70
(63-77.1)
92.1
(86.3-98.2)
III-IV 12
(8-17)
6
(4-9)
00 0
In each case the mean values for the 3 animals are shown, with the range in brackets.
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Page 9 of 14Figure 6 The relationship between PPD, nNOS, parvalbumin, NPY and galanin. Confocal scans from the superficial dorsal horn to show
staining for PPD and four other compounds that have been detected in subsets of inhibitory interneurons: nNOS, parvalbumin (PV), NPY and
galanin (Gal). In each case the image on the left shows PPD (magenta), the one in the middle shows the other compound (green), while the
one on the right is a merged image. a-c: a scan through lamina I and the outer part of lamina II shows a PPD-immunoreactive cell (arrow) close
to 2 nNOS
+ cells (arrowheads). d-f: a scan through the middle part of lamina II shows a PPD
+ cell (arrow) and two parvalbumin cells
(arrowheads). Note that the upper part of this field (lamina IIo) contains numerous PPD-immunoreactive profiles and little parvalbumin staining,
while the lower part (lamina IIi) has many parvalbumin-containing structures, and relatively few that are PPD
+. g-i: a field from lamina II that
contains two PPD cells (arrows) and two NPY cells (arrowheads). Note the lack of co-localisation of PPD with nNOS, parvalbumin or NPY in these
images. j-l: a scan through laminae I and IIo shows 3 PPD cells. Two of these (arrowheads) are also galanin-immunoreactive, while the other one
(arrow) is not. Images were obtained from 3 (a-f) or 4 (g-l) confocal images at 0.5 μm z-spacing. Scale bar = 20 μm.
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Page 10 of 14Although the majority of the PPD
+ neurons in the
superficial dorsal horn were GABA-immunoreactive,
and were therefore inhibitory interneurons, half of those
in lamina I and 20% of those in lamina II were not
stained with the GABA antibody, and these were pre-
sumably glutamatergic (excitatory) cells. This interpreta-
tion is consistent with the finding that PPD is co-
localised with VGLUT2 in some axons within the super-
ficial dorsal horn [35]. The glutamatergic PPD cells in
lamina I are likely to include projection neurons.
Although the early studies that demonstrated dynorphin
in lamina I spinoparabrachial neurons [30,32] used col-
chicine, which may have resulted in de novo expression
of the peptide, Li et al. [39] reported that ~7% of lamina
I trigeminothalamic neurons were PPD-immunoreactive.
Marvizon et al. [35] did not detect PPD staining in the
cell bodies of neurons with the neurokinin 1 receptor,
which is found on ~80% of lamina I projection neurons
[78], and it is therefore possible that dynorphin expres-
sion is restricted to those projection cells that do not
possess this receptor.
Little is known about the types of excitatory inter-
neuron that contain PPD. Several neurochemical mar-
kers for subsets of excitatory interneurons have been
identified, including neuropeptides (e.g. somatostatin
and neurotensin), neuropeptide receptors (e.g. the μ-
opioid receptor MOR-1) and other proteins (e.g. PKCg).
Marvizon et al. [35] reported that PPD was not present
in cells that were labelled with antibodies to either
MOR-1 or PKCg. The lack of overlap with PKCg is not
surprising, since PKCg-expressing neurons are concen-
trated in lamina IIi and lamina III, where PPD neurons
were very scarce. However, MOR-1-immunoreactive
cells, which make up around 10% of all lamina II neu-
rons [79], are found throughout the depth of the lamina
[80], and the lack of coexistence of MOR-1 with PPD
therefore suggests that dynorphin is expressed by speci-
fic types of excitatory interneuron.
Dynorphin-containing neurons in the spinal cord
show considerable plasticity. The peptide can be
strongly up-regulated in both superficial and deep parts
of the dorsal horn in various pain states [31,37,38].
Further studies will be needed to determine whether
these changes affect both excitatory and inhibitory neu-
rons in the superficial laminae.
Subpopulations of inhibitory interneurons in the
superficial dorsal horn
We have previously identified four distinct populations
of inhibitory interneurons in laminae I-III, based on the
expression of different neurochemical markers: NPY,
galanin, nNOS and parvalbumin [47,64]. Although all
NPY and galanin cells in this region are GABAergic
[69,81], some of the cells that contain parvalbumin
[64,82] or nNOS [61] are non-GABAergic. These popu-
lations of inhibitory interneurons have characteristic
laminar distribution patterns: those that contain galanin
are highly concentrated in lamina I and IIo, the parval-
bumin cells are largely restricted to the inner part of
lamina II and lamina III, while cells that contain NPY or
nNOS are found throughout laminae I-III. Although
there is a small group of neurons in lamina III that con-
tain both galanin and nNOS, apart from this there is
virtually no co-localisation of any of these compounds
within neurons in this region, indicating that these four
markers can be used to define distinct, non-overlapping
populations of inhibitory interneurons [47]. We have
also estimated that cells belonging to these four popula-
tions account for around two thirds of the inhibitory
interneurons in lamina I, and half of those in lamina II
[61].
The present results demonstrate that half of the PPD
cells in lamina I and the great majority (80%) of those
in lamina II are GABAergic, and that these cells are lar-
gely equivalent to one of the neurochemical classes that
we have previously defined: those that contain galanin.
In both lamina I and lamina II, the proportion of PPD
neurons that contained GABA (47% and 79%, respec-
tively) and the proportion of those that contained gala-
nin (47% and 70%) were very similar, and the great
majority of the galanin cells in both laminae were PPD
+.
Taken together with the fact that all galanin cells are
thought to be GABAergic [81], these findings indicate
Figure 7 Co-localisation of PPD and galanin in GABAergic
boutons. a-c: Confocal images scanned to reveal PPD (red), galanin
(Gal, green) and VGAT (blue). d: a merged image. This field from
lamina IIo contains two boutons (arrows) that are immunoreactive
with all 3 antibodies. Note that several boutons that are
immunoreactive only for galanin are also present, and these are
likely to belong to peptidergic primary afferent axons, which also
contain galanin. The images are from a single optical section. Scale
bar = 5 μm.
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Page 11 of 14that dynorphin-expressing cells in the superficial lami-
nae can be divided into 2 main groups: a population of
PPD
+/galanin
+ inhibitory interneurons, which are pre-
sent throughout laminae I and IIo, and a smaller popu-
lation of PPD
+/galanin
- excitatory neurons, most of
which are located in lamina I.
PPD is present in 17% of the neurons in lamina I and
4.3% of those in lamina II, and since 47% and 79%,
respectively, of these are GABAergic, we estimate that
PPD
+/GABA
+ cells constitute 8% of all neurons in
lamina I and 3.4% of those in lamina II. We have pre-
viously reported that in the L4/5 segments of Sprague-
Dawley rats, GABAergic cells make up 24.8% of the
neuronal population in lamina I and 31.3% of that in
lamina II [3]. If we assume that the proportions are
similar in Wistar rats, then PPD would be present in
~32% of the inhibitory interneurons in lamina I and
11% of those in lamina II. We have previously estimated
that galanin-containing cells (which overlap extensively
with the PPD population) account for 26% and 10% of
GABAergic neurons in laminae I and II, respectively
[47].
As expected from the extensive co-localisation of PPD
and galanin in cell bodies, they were also co-localised in
most GABAergic boutons that contained either peptide.
Interestingly, both PPD and galanin were found in a
relatively small proportion of GABAergic boutons in
laminae I and II: ~4% in both laminae for PPD (present
study) and 6 and 3%, respectively, for galanin [47]. Since
cells that contain these peptides make up a far higher
proportion of the GABAergic cells in these laminae, this
suggests that these neurons may generate relatively
small axonal arbors compared to other types of inhibi-
tory interneuron in this region, and that they are there-
fore under-represented among GABAergic axons within
the superficial dorsal horn.
Ross et al. [5] have recently shown that mice lacking
the transcription factor Bhlhb5 develop skin lesions that
are thought to result from a heightened sensation of
itch, and that this behavioural phenotype depends on
the loss of a set of dorsal horn inhibitory interneurons
that normally express Bhlhb5. They also reported that
in wild-type mice the transcription factor could be
detected in restricted populations of inhibitory and exci-
tatory neurons for up to two weeks after birth. We have
f o u n dt h a ti nn e o n a t a lm i c eP PD-immunoreactive cells
have a similar distribution to that seen in adult rats,
with numerous cells being present in the superficial dor-
sal horn, and that virtually all of the PPD
+ cells express
Bhlhb5 (E. Polgar, A.J. Todd and S.E. Ross, unpublished
data). This raises the possibility that the dynorphin-
expressing inhibitory interneurons may play a role in
the prevention of itch.
Conclusions
The neuronal organisation of the superficial dorsal horn
is extremely complex, and still poorly understood, and
this is largely due to the difficulty in defining discrete
populations of inhibitory and excitatory interneurons.
The present results provide further evidence that a neu-
rochemical approach can be used to identify distinct
classes of inhibitory interneurons, by showing that
dynorphin is largely restricted to those cells that also
express galanin. The ability to identify the axons of
these cells by dual immunolabelling for VGAT with
either PPD or galanin will allow the postsynaptic targets
of these cells to be determined, and this should help to
elucidate their role in the synaptic circuitry of the dorsal
horn.
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